Blood-Derived Biomaterial for Catheter-Directed Arterial Embolization

Area of Science:

• Biomaterials Science
• Interventional Radiology
• Regenerative Medicine

Background:

• Vascular embolization uses metallic coils to stop bleeding but has drawbacks like cost and availability.
• Current embolic materials have limitations that hinder their widespread clinical application.

Purpose of the Study:

• To develop and evaluate a novel blood-derived embolic material (BEM) with regenerative properties for vascular embolization.
• To assess the efficacy and safety of BEM in achieving rapid and durable hemostasis in a large animal model.

Main Methods:

• A novel blood-derived embolic material (BEM) was prepared at the point-of-care within 26 minutes using fresh blood.
• BEM was delivered via clinical catheters to embolize renal and iliac arteries in a large animal model.
• Vessel healing, including cellular proliferation, angiogenesis, and connective tissue deposition, was assessed post-embolization.

Main Results:

• BEM achieved instant and durable intra-arterial hemostasis, regardless of coagulopathy.
• The material was easily delivered using standard catheters and demonstrated rapid hemostasis in acutely injured swine arteries.
• BEM promoted cellular proliferation, angiogenesis, and connective tissue deposition, indicating vessel healing and durable occlusion.

Conclusions:

• The novel blood-derived embolic material (BEM) is a promising alternative to current embolic agents.
• BEM offers advantages in preparation time, delivery, hemostatic efficacy, and regenerative properties.
• This innovative material shows potential for improving outcomes in vascular embolization procedures.